Psychiatric Disorders

Neuronetics Inc (NASDAQ: STIM) boasts a therapy that addresses a pressing medical need, according to JMP Securities.  The Analyst Analyst David Turkaly initiated coverage of Neuronetics with an Outperform rating and $36 price target. The Thesis For patients who have failed one of...